Sarepta Therapeutics Announces Conference Call and Webcast on Wednesday, October 3, 2012, to Discuss 48-Week Results From the Phase IIb DMD Study
(firmenpresse) - CAMBRIDGE, MA -- (Marketwire) -- 10/02/12 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Wednesday, October 3, 2012 to discuss 48-week results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).
The conference call may be accessed by dialing 866.356.3093 for domestic callers and 617.597.5381 for international callers. The passcode for the call is 93880948. Please specify to the operator that you would like to join the "Sarepta Therapeutics 48-Week Results Call." The conference call will be webcast live under the events section of Sarepta's website at and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at .
Sarepta Investor and Media Contact:
Erin Cox
425.354.5140
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2012 - 20:30 Uhr
Sprache: Deutsch
News-ID 189011
Anzahl Zeichen: 0
contact information:
Town:
CAMBRIDGE, MA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 269 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sarepta Therapeutics Announces Conference Call and Webcast on Wednesday, October 3, 2012, to Discuss 48-Week Results From the Phase IIb DMD Study"
steht unter der journalistisch-redaktionellen Verantwortung von
Sarepta Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
